S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

$51.25
+0.40 (+0.79%)
(As of 06/5/2023 ET)
Compare
Today's Range
$50.05
$51.93
50-Day Range
$37.33
$51.42
52-Week Range
$33.36
$68.68
Volume
554,270 shs
Average Volume
631,404 shs
Market Capitalization
$3.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.25

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
74.8% Upside
$90.25 Price Target
Short Interest
Bearish
5.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
1.14mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$297,610 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.35) to ($6.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

269th out of 985 stocks

Pharmaceutical Preparations Industry

124th out of 488 stocks


RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (RARE)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Wedbush Remains a Hold on Ultragenyx Pharmaceutical (RARE)
See More Headlines

RARE Price History

RARE Company Calendar

Last Earnings
5/04/2023
Today
6/05/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,311
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$90.25
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+77.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-707,420,000.00
Net Margins
-187.31%
Pretax Margin
-185.85%

Debt

Sales & Book Value

Annual Sales
$363.33 million
Book Value
$5.03 per share

Miscellaneous

Free Float
65,999,000
Market Cap
$3.60 billion
Optionable
Optionable
Beta
0.90

Social Links


Key Executives

  • Emil D. KakkisEmil D. Kakkis
    President, Chief Executive Officer & Director
  • Dennis Karl HuangDennis Karl Huang
    Chief Technical Operations Officer & Senior VP
  • Eric Crombez
    Chief Medical Officer & Executive Vice President
  • Samuel C. Wadsworth
    Chief Scientific Officer
  • Thomas Richard KassbergThomas Richard Kassberg
    Chief Business Officer & Executive Vice President













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2023?

12 equities research analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $50.00 to $142.00. On average, they expect the company's stock price to reach $90.25 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2023?

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of the year. Since then, RARE stock has increased by 11.4% and is now trading at $51.62.
View the best growth stocks for 2023 here
.

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,490,000 shares, an increase of 17.1% from the April 30th total of 2,980,000 shares. Based on an average daily volume of 637,500 shares, the short-interest ratio is presently 5.5 days. Currently, 5.3% of the shares of the stock are sold short.
View Ultragenyx Pharmaceutical's Short Interest
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.97) by $0.36. The biopharmaceutical company had revenue of $100.50 million for the quarter, compared to analysts' expectations of $103.90 million. Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative trailing twelve-month return on equity of 149.75%. The firm's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.19) EPS.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $435.57 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.22%), BlackRock Inc. (6.90%), RTW Investments LP (6.04%), Price T Rowe Associates Inc. MD (5.01%), State Street Corp (3.89%) and Clearbridge Investments LLC (3.82%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $51.62.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.66 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.25) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,311 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -